ComplianceOnline

Adverse Event Reporting to IRBs – Best Practices to Follow

  • By: Staff Editor
  • Date: December 01, 2011
Webinar All Access Pass Subscription Abstract:

The Food and Drug Administration (FDA) has issued guidelines for adverse event reporting because adverse event reports were found to be inhibiting, rather than enhancing, the ability of IRBs to protect the human subjects.

This article describes the best practices to be followed in order to comply with the FDA's new guidelines on adverse event reporting to IRBs.

Bookmark and Share

Trending Compliance Trainings

Risk Based Monitoring for GCP Compliance
By - Laura Brown
On Demand Access Anytime
Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
Annual Current Good Manufacturing Practices (cGMP) Training
By - Kelly Thomas
On Demand Access Anytime
Issues related to informed consent in clinical trials
By - Sarah Fowler Dixon
On Demand Access Anytime
How to write a Clinical Evaluation
By - Rebecca Kemble
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading